DDInter128 DDInter1658
Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Astemizole {u} (Compound) resembles {v} (Compound) Fentanyl
Astemizole {u} (Compound) resembles {v} (Compound) Flunarizine
Astemizole {u} may lead to a major life threatening interaction when taken with {v} Pimozide
Astemizole {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Astemizole {u} (Compound) upregulates {v} (Gene) LIPA
Astemizole {u} (Compound) downregulates {v} (Gene) RPS4Y1
Astemizole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Astemizole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Astemizole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Astemizole {u} may lead to a major life threatening interaction when taken with {v} Methadone
Astemizole (Compound) resembles Fentanyl (Compound)
Astemizole (Compound) resembles Flunarizine (Compound)
Astemizole may lead to a major life threatening interaction when taken with Pimozide
Astemizole (Compound) binds CYP3A7-CYP3A51P (Gene)
Astemizole (Compound) upregulates LIPA (Gene)
Astemizole (Compound) downregulates RPS4Y1 (Gene)
Astemizole may cause a minor interaction that can limit clinical effects when taken with Modafinil
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib
Astemizole may lead to a major life threatening interaction when taken with Methadone